Tepotinib + Ivonescimab for Non-Small Cell Lung Cancer

This trial aims to determine if a combination of two drugs, tepotinib and ivonescimab, is safe and effective for treating non-small cell lung cancer (NSCLC) with a specific genetic change called METex14 skipping. Researchers will test different doses of tepotinib to identify the one with the fewest side effects. This trial may suit individuals with advanced NSCLC with the METex14 skipping change who have not received certain previous treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial protocol does not specify if you need to stop taking your current medications. However, you must not have had prior systemic therapy within 21 days of starting the trial, and certain medications like anticoagulants must be stable before joining. It's best to discuss your specific medications with the trial team.

Research has shown that the U.S. Food and Drug Administration has fully approved tepotinib for treating certain types of lung cancer. This approval indicates that it has passed strict safety checks for those uses and is considered safe for many patients.

Ivonescimab, when combined with chemotherapy, demonstrated a safety profile similar to other treatments, meaning it did not cause more side effects than the treatments it was compared to. Studies found that side effects were manageable, and no new safety concerns emerged.

Researchers are excited about tepotinib and ivonescimab for non-small cell lung cancer (NSCLC) because they offer a different approach compared to traditional chemotherapy and targeted therapies like EGFR inhibitors. Tepotinib is a MET inhibitor, which targets specific genetic alterations in cancer cells, potentially leading to more effective and personalized treatment. Ivonescimab, on the other hand, is a bispecific antibody that simultaneously targets two pathways, potentially enhancing the immune system’s ability to attack the cancer. This combination aims to improve outcomes by addressing both genetic drivers of cancer and enhancing immune response, offering a novel strategy for tackling NSCLC.

Studies have shown that tepotinib effectively treats metastatic non-small cell lung cancer (NSCLC). The FDA has approved it, indicating its proven benefit for many patients. Research also shows that ivonescimab, when combined with chemotherapy, extends the lives of NSCLC patients more effectively than treatments like tislelizumab, reducing the risk of death by 34%. This trial will evaluate the combination of tepotinib and ivonescimab, which could offer a promising treatment for NSCLC with a specific genetic change called METex14 skipping.¹²³⁴⁵